
New phone system at TWINCORE
Some extension numbers have changed.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

Some extension numbers have changed.

zukunft.niedersachsen provides €2.7 million in funding for joint project on rare diseases

€100,000 from the German Society for Parkinson's Disease and Movement Disorders
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Zhang Y, Matzaraki V, Vadaq N, Blaauw M, Vos W, Groenendijk A, van Eekeren L, Stalenhoef J, Berrevoets M, Rokx C, Delporte M, Otten T, Joosten L, Xu C, Li Y, Vandekerckhove L, van der Ven A, Netea M
Mayer L, Arnold J, Roettele F, Reuter N, Pattekar A, Ohtani T, Ribeiro M, Siwicki R, Bruder K, Obwegs D, Stahl E, Buechel S, Roehlen N, Kolter J, Mansoori Moghadam Z, Alaswad A, Zhumalidova Z, Li G, Liu X, Li Y, Singh A, Villacorta Hidalgo J, Paraskevopoulou M, Yajnik V, Juarez J, Ren Y, Li H, Wherry E, Lewis J, Wu G, Bewtra M, Tomov V, Thimme R, Bengsch B, Hasselblatt P, Picelli S, Hofmann M, Sagar
Zhan Q, Zhou L, Fu J, Jiang X, Liu X, Li W, Moorlag S, Koeken V, de Bree L, Mourits V, Joosten L, Li Y, Netea M, Xu C
The project investigates immune reactions in viral hepatitis, in particular the role of hepatocytes and myeloid cells. The aim is to understand immune processes in the liver and to develop diagnostic approaches for the clinic.
The project will investigate the immunological and genetic causes of vaccination failure in 5% of HBV-vaccinated individuals in order to develop new strategies to improve vaccination protection.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.

